Publication | Open Access

Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents

Medicinal ChemistryPharmaceutical ChemistryPyridine SorafenibMedicinePharmacotherapyAnti-cancer AgentDrug DevelopmentPotential Braf InhibitorsPharmacologyRadiation OncologyAnti-tumor AgentsDrug Discovery